🚀 VC round data is live in beta, check it out!
Arcutis Biotherapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Arcutis Biotherapeutics and similar public comparables like Arcus Biosciences, Sinocelltech Group, Vera Therapeutics, Grand Pharmaceutical and more.
Arcutis Biotherapeutics Overview
About Arcutis Biotherapeutics
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Founded
2016
HQ
Employees
354
Website
Sectors
Financials (LTM)
EV
$3B
Arcutis Biotherapeutics Financials
Arcutis Biotherapeutics reported last 12-month revenue of $413M and EBITDA of $33M.
In the same LTM period, Arcutis Biotherapeutics generated $372M in gross profit, $33M in EBITDA, and $2M in net income.
Revenue (LTM)
Arcutis Biotherapeutics P&L
In the most recent fiscal year, Arcutis Biotherapeutics reported revenue of $376M and EBITDA of $11M.
Arcutis Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $413M | XXX | $376M | XXX | XXX | XXX |
| Gross Profit | $372M | XXX | $339M | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | $33M | XXX | $11M | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 3% | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | (3%) | XXX | XXX | XXX |
| Net Profit | $2M | XXX | ($16M) | XXX | XXX | XXX |
| Net Margin | 1% | XXX | (4%) | XXX | XXX | XXX |
| Net Debt | — | — | $66M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Arcutis Biotherapeutics Stock Performance
Arcutis Biotherapeutics has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Arcutis Biotherapeutics' stock price is $24.55.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.0% | XXX | XXX | XXX | $-0.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialArcutis Biotherapeutics Valuation Multiples
Arcutis Biotherapeutics trades at 7.1x EV/Revenue multiple, and 87.8x EV/EBITDA.
EV / Revenue (LTM)
Arcutis Biotherapeutics Financial Valuation Multiples
As of April 19, 2026, Arcutis Biotherapeutics has market cap of $3B and EV of $3B.
Equity research analysts estimate Arcutis Biotherapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arcutis Biotherapeutics has a P/E ratio of 1263.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 7.1x | XXX | 7.8x | XXX | XXX | XXX |
| EV/EBITDA | 87.8x | XXX | 276.8x | XXX | XXX | XXX |
| EV/EBIT | 472.3x | XXX | (240.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 7.9x | XXX | 8.7x | XXX | XXX | XXX |
| P/E | 1263.8x | XXX | (188.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (180.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Arcutis Biotherapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Arcutis Biotherapeutics Margins & Growth Rates
Arcutis Biotherapeutics' revenue in the last 12 month grew by 31%.
Arcutis Biotherapeutics' revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $1.0M for the same period.
Arcutis Biotherapeutics' rule of 40 is 50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Arcutis Biotherapeutics' rule of X is 99% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Arcutis Biotherapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 31% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Growth | 253% | XXX | 721% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 50% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 99% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 19% | XXX | 20% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 93% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Arcutis Biotherapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Arcutis Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcus Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Sinocelltech Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Vera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Grand Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Apeloa Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arcutis Biotherapeutics M&A Activity
Arcutis Biotherapeutics acquired XXX companies to date.
Last acquisition by Arcutis Biotherapeutics was on XXXXXXXX, XXXXX. Arcutis Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Arcutis Biotherapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialArcutis Biotherapeutics Investment Activity
Arcutis Biotherapeutics invested in XXX companies to date.
Arcutis Biotherapeutics made its latest investment on XXXXXXXX, XXXXX. Arcutis Biotherapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Arcutis Biotherapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Arcutis Biotherapeutics
| When was Arcutis Biotherapeutics founded? | Arcutis Biotherapeutics was founded in 2016. |
| Where is Arcutis Biotherapeutics headquartered? | Arcutis Biotherapeutics is headquartered in United States. |
| How many employees does Arcutis Biotherapeutics have? | As of today, Arcutis Biotherapeutics has over 354 employees. |
| Who is the CEO of Arcutis Biotherapeutics? | Arcutis Biotherapeutics' CEO is Todd Franklin Watanabe. |
| Is Arcutis Biotherapeutics publicly listed? | Yes, Arcutis Biotherapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Arcutis Biotherapeutics? | Arcutis Biotherapeutics trades under ARQT ticker. |
| When did Arcutis Biotherapeutics go public? | Arcutis Biotherapeutics went public in 2020. |
| Who are competitors of Arcutis Biotherapeutics? | Arcutis Biotherapeutics main competitors are Arcus Biosciences, Sinocelltech Group, Vera Therapeutics, Grand Pharmaceutical. |
| What is the current market cap of Arcutis Biotherapeutics? | Arcutis Biotherapeutics' current market cap is $3B. |
| What is the current revenue of Arcutis Biotherapeutics? | Arcutis Biotherapeutics' last 12 months revenue is $413M. |
| What is the current revenue growth of Arcutis Biotherapeutics? | Arcutis Biotherapeutics revenue growth (NTM/LTM) is 31%. |
| What is the current EV/Revenue multiple of Arcutis Biotherapeutics? | Current revenue multiple of Arcutis Biotherapeutics is 7.1x. |
| Is Arcutis Biotherapeutics profitable? | Yes, Arcutis Biotherapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Arcutis Biotherapeutics? | Arcutis Biotherapeutics' last 12 months EBITDA is $33M. |
| What is Arcutis Biotherapeutics' EBITDA margin? | Arcutis Biotherapeutics' last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of Arcutis Biotherapeutics? | Current EBITDA multiple of Arcutis Biotherapeutics is 87.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.